A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
EMD Serono Research & Development Institute, Inc.

Protocol Number
EMR 200647-001

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications